These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17972958)

  • 1. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
    Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
    Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
    [No Abstract]   [Full Text] [Related]  

  • 2. JAK2-V617F and BCR-ABL--double jeopardy?
    Krämer A
    Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
    [No Abstract]   [Full Text] [Related]  

  • 3. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
    Pingali SR; Mathiason MA; Lovrich SD; Go RS
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):E25-9. PubMed ID: 19858050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.
    Kim YK; Shin MG; Kim HR; Yang DH; Cho SH; Lee JJ; Chung IJ; Ryang DW; Kim HJ
    Leuk Res; 2008 Jun; 32(6):993-5. PubMed ID: 18055011
    [No Abstract]   [Full Text] [Related]  

  • 5. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
    Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
    Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
    [No Abstract]   [Full Text] [Related]  

  • 6. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.
    Cross NC; Daley GQ; Green AR; Hughes TP; Jamieson C; Manley P; Mughal T; Perrotti D; Radich J; Skoda R; Soverini S; Vainchenker W; Verstovsek S; Villeval JL; Goldman JM
    Leukemia; 2008 Nov; 22(11):1975-89. PubMed ID: 19002192
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
    Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
    Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
    [No Abstract]   [Full Text] [Related]  

  • 8. Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
    Nakata Y
    Hiroshima J Med Sci; 1993 Jun; 42(2):67-71. PubMed ID: 8253600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report.
    Ursuleac I; Colita A; Adam T; Jardan C; Ilea A; Coriu D
    J Med Life; 2013 Mar; 6(1):34-7. PubMed ID: 23599815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.
    Bader G; Dreiling B
    J Investig Med High Impact Case Rep; 2019; 7():2324709619832322. PubMed ID: 30803277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
    Luque Paz D; Ianotto JC; Chauveau A; Guibourg B; Lecucq L; Lippert E; Ugo V
    Ann Hematol; 2016 Jan; 95(2):349-50. PubMed ID: 26459144
    [No Abstract]   [Full Text] [Related]  

  • 12. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
    Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E
    Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.
    Suzuki R; Onizuka M; Kojima M; Shimada M; Tsuboi K; Ogawa Y; Kawada H; Ando K
    Tokai J Exp Clin Med; 2007 Dec; 32(4):131-5. PubMed ID: 21318952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.
    Go RS
    Leukemia; 2007 Sep; 21(9):2051; author reply 2052. PubMed ID: 17597806
    [No Abstract]   [Full Text] [Related]  

  • 16. Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ; Kim DY; Lee JH; Lee KH
    Ann Lab Med; 2013 May; 33(3):229-32. PubMed ID: 23667855
    [No Abstract]   [Full Text] [Related]  

  • 17. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.
    Jallades L; Hayette S; Tigaud I; Johnston A; Coiffier B; Magaud JP; Ffrench M
    Leuk Res; 2008 Oct; 32(10):1608-10. PubMed ID: 18448166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
    Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
    Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
    Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
    Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
    [No Abstract]   [Full Text] [Related]  

  • 20. JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
    Pahore ZA; Shamsi TS; Taj M; Farzana T; Ansari SH; Nadeem M; Ahmad M; Naz A
    J Coll Physicians Surg Pak; 2011 Aug; 21(8):472-5. PubMed ID: 21798133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.